Clinical features | CYP19A1 | ||||
---|---|---|---|---|---|
rs10046 | rs7176005 | rs700519 | rs6493497 | rs4646 | |
Body mass index b n = 221 | 0.510 | 0.570 | 0.811 | 0.547 | 0.092 |
Age at first pregnancy b n = 195 | 0.122 | 0.200 | 0.825 | 0.200 | 0.956 |
Age at BC diagnosis b n = 221 | 0.007 | 0.681 | 0.836 | 0.789 | 0.921 |
Allergy a n = 221 | 0.936 | 0.935 | 0.401 | 0.967 | 0.856 |
Age at menarche b n = 221 | 0.989 | 0.421 | 0.044 | 0.405 | 0.383 |
Breastfeeding status a n = 221 | 0.401 | 0.095 | 0.367 | 0.127 | 0.721 |
Age at menopause b n = 108 | 0 .290 | 0.736 | 0 .002 | 0 .736 | 0.797 |
Family history a n = 221 | 0.571 | 0.121 | 0.927 | 0.138 | 0.123 |
Co-morbidity a n = 221 | 0.104 | 0.557 | 0.924 | 0.566 | 0.905 |
Smoking a n = 216 | 0.166 | 0.607 | 0.059 | 0.580 | 0.617 |
Pathological features | |||||
Progesterone receptor status a n = 198 | 0.157 | 0.754 | 0.867 | 0.719 | 0.755 |
Estrogen receptor status a n = 191 | 0.714 | 0.463 | 0.159 | 0.339 | 0.227 |
Human epidermal growth factor receptor 2 marker (HER2) a n = 139 | 0.945 | 0.445 | 0.493 | 0.485 | 0.468 |
Heteromolecular BC markersa n = 138 | 0.510 | 0.788 | 0.915 | 0.797 | 0.754 |
Tumor differentiation a n = 197 | 0.273 | 0.851 | 0.918 | 0.860 | 0.906 |
Axillary lymph nodes a n = 221 | 0.844 | 0.793 | 0.584 | 0.687 | 0.297 |
Tumor stage a n = 208 | 0.491 | 0.118 | 0.922 | 0.080 | 0.236 |
Histology classification a n = 209 | 0.722 | 0.475 | 0.407 | 0.507 | 0.320 |
Tumor size b n = 208 | 0.726 | 0.547 | 0.879 | 0.472 | 0.448 |
Lymph node involvement a n = 221 | 0.953 | 0.681 | 0.617 | 0.691 | 0.022 |